Facebook
Twitter
LinkedIn
Forward
The Role for Consolidative Local Therapy in Stage IV Non-Small Cell Lung Cancer for Oligometastases and Beyond: How are We Improving Outcomes for Patients?
Patients with Stage IV Lung cancer vary in their response to the numerous systemic therapies and are living longer. The role of aggressive local therapy or metastatic directed therapy (MDT) is critical for radiation oncologists and surgeons. It is important for clinicians to recognize that patients with limited metastatic burden could potentially derive progressive disease and survival benefits from MDT. The aim is to present difficult cases for patients with Stage IV Lung cancer to discuss evidence for the clinical benefit of aggressive local therapy with radiation or surgery. These patients will include those with oligometastases and oligoprogression of lung cancer. The speakers discuss technological advances in MDT, which patients may derive benefit from local therapy, and treatment recommendations. The speakers also discuss the need for multidisciplinary care with systemic therapy and local therapy for optimal management for patients with metastatic lung cancer.
Topic:
- Introductions
Quynh-Nhu Nguyen, MD - The Role for Surgery in Stage IV NSCLC: Moving the Needle for Operable Disease and Difficult Cases
Mara Antonoff, MD - Consolidative Radiation Therapy Beyond Oligometastases in Stage IV NSCLC, Treatment Approaches with More Curative Intent and Difficult Cases
C. Jillian Tsai, MD, PhD, MS - Stage IV Non-Small Cell Lung Cancer - Which Patients with Actionable Mutations Survive Longer and Should be Approached and Treated with More Curative Intent?
Carl Michael Gay, MD, PhD
This activity is available from July 9, 2024, through 11:59 p.m. Eastern time on July 8, 2026.
This activity was originally recorded at the 2023 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Allow attendees the opportunity to learn about the latest clinical research.
- Learn the guidelines on treating Stage IV Lung cancer, and understand the wide spectrum of patients who benefit from a multidisciplinary approach.
- Know which patients can benefit from aggressive local therapy and understand the advanced technology used to improve patient outcomes.
- Quynh-Nhu Nguyen, MD, is employed by The University of Texas MD Anderson Cancer Center.
- Mara Antonoff, MD, is employed by The University of Texas MD Anderson Cancer Center. Dr. Antonoff receives compensation for consulting from AstraZeneca.
- C. Jillian Tsai, MD, PhD, MS, is employed by Princess Margaret Cancer Centre, University Health Network. Dr. Tsai receives grant/research funding and honoraria from Varian Medical Inc. Dr. Tsai serves on the Advisory Board of Nanobiotix (uncompensated). Dr. Tsai is the Deputy Editor of Advances in Radiation Oncology.
- Carl Michael Gay, MD, PhD, is employed by The University of Texas MD Anderson Cancer Center and the University of Texas Health Science Center. Dr. Gay receives travel expenses from AstraZeneca and G1 Therapeutics.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
Nonmember: $149
Member: $99
Member-in-training: $49
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website until July 8, 2026, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.